干细胞移植对终末期肝病患者免疫、肝功能及相关指标的影响

发布时间：2018-03-25 15:31

  本文选题：骨髓　切入点：间质干细胞移植　出处：《重庆医学》2017年18期

【摘要】：目的探讨干细胞移植对终末期肝病(ESLD)前后患者免疫、肝功能及相关指标影响。方法选取郑州大学附属医院南阳市中心医院ESLD患者163例,随机单盲取法分为2组,对照组81例给予常规、对症治疗,观察组82例在对照组基础上给予骨髓间充质干细胞(BMSC)移植,观察两组治疗前后免疫、肝功能及甲胎球蛋白(AFP)、凝血酶原活动率(PTA)、血浆总蛋白(TP)水平变化。结果观察组治疗后免疫功能指标CD3~+、CD4~+、CD8~+、CD4~+/CD8~+比值、TP、PTA水平均高于同组治疗前及对照组同期(P0.05),AFP、丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)均低于同组治疗前及对照组同期(P0.05)。两组患者并发症发生率比较,差异无统计学意义(P0.05)。结论 BMSC移植治疗ESLD,可改善患者免疫功能,提高肝功能,降低AFP水平。
[Abstract]:Objective to investigate the effect of stem cell transplantation on immunity, liver function and related indexes in patients with end-stage liver disease before and after ESLD. Methods 163 patients with ESLD in Nanyang Central Hospital, affiliated Hospital of Zhengzhou University, were randomly divided into two groups. 81 cases in the control group were treated with routine and symptomatic therapy, 82 cases in the observation group were transplanted with bone marrow mesenchymal stem cells (BMSC) on the basis of the control group, and the two groups were immunized before and after treatment. Results after treatment, the levels of immunological function index CD3 ~ + CD4 ~ + CD8 ~ + CD8 ~ + / CD8 ~ + and TPPTA in the observation group were higher than those in the same group and the control group before treatment and in the control group. The incidence of complications in the two groups was lower than that in the same group before treatment and in the control group (P 0.05), and the levels of alt, aspartate transaminase and total bilirubin TBILwere lower than those in the control group. Conclusion BMSC transplantation can improve the immune function, improve liver function and decrease the level of AFP in patients with ESLD.
【作者单位】： 郑州大学附属医院南阳市中心医院感染科;南阳医学高等专科学校基础医学部;
【基金】：河南省卫生厅科研成果项目[宛科鉴字(2012)第103号99]
【分类号】：R575.3
，

本文编号：1663737